Avadel Pharmaceuticals plc - Ordinary Share (AVDL)
7.4600
-0.0500 (-0.67%)
NASDAQ · Last Trade: Apr 2nd, 7:56 PM EDT

Insiders are buying these three stocks. The underlying companies have robust growth outlooks and are on track to deliver in 2025.
Via MarketBeat · February 19, 2025

Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025.
Via MarketBeat · January 20, 2025

Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades.
Via Benzinga · January 17, 2024

Avadel Pharmaceuticals missed the fourth quarter sales estimate by 5.12%. Still, the sales of its narcolepsy drug, LUMRYZ rose by 150% YoY.
Via Benzinga · January 9, 2025

Via Benzinga · December 19, 2024

Via Benzinga · October 31, 2024

AVDL stock results show that Avadel Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 8, 2024

On Tuesday, Avadel Pharmaceuticals stock received a positive adjustment to its Relative Strength (RS) Rating, from 76 to 82.
Via Investor's Business Daily · August 6, 2024

Via Benzinga · December 20, 2023

AVDL stock results show that Avadel Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 8, 2024

Via Benzinga · March 28, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via Benzinga · March 5, 2024

Avadel Pharmaceuticals plc (NASDAQ: AVDL) reported better-than-expected fourth-quarter revenue results and also issued a corporate update on Monday.
Via Benzinga · March 5, 2024

Via Benzinga · March 4, 2024

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its fourth quarter.
Via Benzinga · March 4, 2024

Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on the stock and raised its price target from $35 to $41.
Via Benzinga · January 8, 2024

Avadel Pharmaceuticals plc (NASDAQ: AVDL) recognized $7.0 million in net product revenue for Q3.
Via Benzinga · November 8, 2023

U.S. stocks traded mostly lower, with the Nasdaq Composite falling around 20 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via Benzinga · November 8, 2023

U.S. stocks traded mixed, with the Dow Jones gaining around 80 points on Friday. Here are some big stocks recording gains in today’s session.
Via Benzinga · August 11, 2023